People with type 1 diabetes who need to lose weight can benefit from the blockbuster GLP-1 drug semaglutide currently ...

While Novo Nordisk stock has underperformed since my Strong Buy rating four months ago, the long-term investment thesis ...

With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

The pharmaceutical company alleges Hims is widely selling cheaper versions of its blockbuster drugs, despite the FDA's recent ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for ...

Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Hims & Hers (NYSE:HIMS) just got the cold shoulder from Novo Nordisk (NYSE:NVO). Hims had been compunding its own batches of ...

Novo Nordisk said it will stop selling Wegovy on Hims & Hers, claiming the telehealth company sold knockoff versions of the ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Novo Nordisk continues to expand its partnerships with telehealth companies to broaden access to its blockbuster weight loss ...

Novo Nordisk had been providing Hims & Hers with the FDA-approved Wegovy, an injectable semaglutide used for weight loss ...

Hims & Hers Health continues to eye personalized services and global expansion. Read more on what investors should know about ...